UKHSA (UK) · Jul 29, 2026
Promotional material: Vaccine update: issue 373, July 2026
Latest developments in vaccines, vaccination policies and procedures for immunisation practitioners.
Global Health · page 4
UK, EU & international health agencies
MHRA (UK) · Jul 29, 2026
Guidance: Ambient voice technology-enabled products
Device qualification and classification of ambient voice technology-enabled products that are medical devices intended to be placed on the market, or put into service, in Great Britain.
MHRA (UK) · Jul 29, 2026
Guidance: Digital mental health technology: qualification and classification
Helping manufacturers define the characteristics of their devices and determine the appropriate regulatory qualification and classification.
UKHSA (UK) · Jul 28, 2026
Guidance: Botulism: clinical and public health management
Information for healthcare professionals on the diagnosis and treatment of infant botulism, foodborne botulism and wound botulism.
DHSC (UK) · Jul 28, 2026
Official Statistics: Bioscience and health technology sector statistics 2024 to 2025
Official statistics in development estimating the size and composition of the life sciences sector in the UK.
MHRA (UK) · Jul 28, 2026
Field Safety Notices: 20 to 24 July 2026
List of Field Safety Notices from 20 to 24 July 2026.
UKHSA (UK) · Jul 28, 2026
Guidance: Communicable disease outbreak management guidance
Identification and management of outbreaks and resources to support local health protection system response to outbreaks of communicable disease.
ECDC (EU) · Jul 28, 2026
World Hepatitis Day 2026: Ensuring that life-saving interventions are accessible to everyone who needs them is a common challenge
World Hepatitis Day is an opportunity to raise awareness of the risk of contracting hepatitis and the health threats it can bring, while at the same time recognising the progress Europe has made to strengthen prevention.
ECDC (EU) · Jul 28, 2026
World Hepatitis Day 2026: Despite progress towards eliminating hepatitis in Europe, gaps in prevention measures keep 2030 targets out of reach
While Europe has made steady progress in preventing hepatitis B and C the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat.
NHS England · Jul 27, 2026
Hundreds of thousands of women access free morning-after pill at NHS pharmacies in first 5 months
Hundreds of thousands of women have accessed the morning-after pill at high street pharmacies in the first 5 months since the NHS made it available free-of-charge. New NHS figures show that almost 305,000 doses of the emergency contraceptive pill were supplied at pharmacies between October 2025 and March 2026 without women needing to book a […]
MHRA (UK) · Jul 27, 2026
Safety Public Assessment Reports
These reports explain our assessment of the scientific evidence used to lead to regulatory decisions on the safety of medicines or medicines classes.
MHRA (UK) · Jul 27, 2026
Research: Bladder Anticholinergics: review of risk of dementia
Public Assessment Report on the safety review of the available data on the risk of dementia with the use of bladder anticholinergic medicines.
UKHSA (UK) · Jul 27, 2026
UKHSA updates heat health alerts across England
An amber heat-health alert has been issued for the East Midlands, East of England, South East and London.
DHSC (UK) · Jul 27, 2026
Transparency data: DHSC: workforce management information June 2026
Reports on departmental staff numbers and costs.
UKHSA (UK) · Jul 24, 2026
Guidance: Meningococcal B (MenB) time limited vaccination offer: eligibility flow chart
Guidance for health professionals delivering the time-limited MenB vaccination offer on the eligible cohort.
DHSC (UK) · Jul 24, 2026
Guidance: Learning Support Fund 10th edition: 2026 to 2027
Information for academic authorities and students on pre-registration healthcare programmes in the 2026 to 2027 academic year.
EMA (EU) · Jul 24, 2026
Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 20-23 July 2026
Twelve new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended twelve medicines for approval at its July 2026 meeting.The committee…, CHMP statistics Key figures from the July 2026 CHMP meeting are represented in the graphic below. © European Medicines Agency , CHMP statistics:…, Positive recommendations on new medicines, Evlarco International non-proprietary name (INN) obicetrapib / ezetimibe Marketing authorisation applicant A. Menarini International Licensing S.A.…, Icotyde INN icotrokinra hydrochloride Marketing authorisation…
MHRA (UK) · Jul 24, 2026
No summer shortcut for safe weight loss
As demand for weight-loss medicines continues to rise, the MHRA is reminding people how to use GLP-1 medicines safely, spot illegal sellers, and avoid diet changes that could interfere with their medicines.
UKHSA (UK) · Jul 23, 2026
Accredited official statistics: Monthly mandatory surveillance of MRSA, MSSA, Gram-negative bacteraemia and C. difficile infections, June 2025 to June 2026
Mandatory surveillance of healthcare-associated infections (HCAI), which include methicillin-resistant Staphylococcus aureus (MRSA), Methicillin-sensitive Staphylococcus aureus (MSSA), Gram-negative bacteraemia such as Escherichia coli (E. coli), Klebsiella and Pseudomonas aeruginosa (P. aeruginosa) and Clostridioides difficile (C. difficile, or CDI): June 2025 to June 2026.
MHRA (UK) · Jul 23, 2026
Guidance: Clinical investigations: compiling a submission
How to notify the MHRA that you are going to undertake a clinical investigation of a medical device.
MHRA (UK) · Jul 23, 2026
Guidance: Medical devices that need a clinical investigation
How to determine if you will need to undertake a clinical investigation of a medical device, or if it is exempt under the regulations.
MHRA (UK) · Jul 23, 2026
Clinical investigations in Great Britain
How manufacturers should undertake a clinical investigation for a medical device to ensure they comply with medical device regulations.
MHRA (UK) · Jul 23, 2026
Guidance: Approving clinical investigations
How the MHRA decides whether to approve a clinical investigation for medical devices.
MHRA (UK) · Jul 23, 2026
Class 4 Medicines Defect Notification: Neuraxpharm UK Ltd, Tuzulby prolonged-release chewable tablets, EL(26)A/36
Neuraxpharm UK Ltd has informed the MHRA of missing safety information in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) for certain batches of Tuzulby prolonged release 20mg, 30mg and 40mg chewable tablets.